NEW YORK, Dec. 17, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced that it has completed manufacture of its required three NDA registration batches of ST-246 drug substance, the Company’s lead smallpox anti-viral.
